Research progress and application of liver organoids for disease modeling and regenerative therapy
Journal of Molecular Medicine · 2024
DOI: 10.1007/s00109-024-02455-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Molecular Medicine, 2024. Verfasst von Yang Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chinese Medicine Modernization and Big Data Research Center, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicin…. Hauptthemen laut MEDLINE: Organoids, Liver, Liver Diseases, Regenerative Medicine. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Province Traditional Chinese Medicine Science and Technology Development Plan Project, Jiangsu Provincial Key Research and Development Program.
Abstract (Originalsprache)
The liver is a major metabolic organ of the human body and has a high incidence of diseases. In recent years, the annual incidence of liver disease has increased, seriously endangering human life and health. The study of the occurrence and development mechanism of liver diseases, discovery of new therapeutic targets, and establishment of new methods of medical treatment are major issues related to the national economy and people’s livelihood. The development of stable and effective research models is expected to provide new insights into the pathogenesis of liver diseases and the search for more effective treatment options. Organoid technology is a new in vitro culture system, and organoids constructed by human cells can simulate the morphological structure, gene expression, and glucose and lipid metabolism of organs in vivo, providing a new model for related research on liver diseases. This paper reviews the latest research progress on liver organoids from the establishment of cell sources and application of liver organoids and discusses their application potential in the field of liver disease research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chinese Medicine Modernization and Big Data Research Center, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210022, Jiangsu, C…
- Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China.
- Department of Angioenterology, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, 157 Daming Avenue, Nanjing, 210022, Jiangsu, China.
- Department of Angioenterology, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, 157 Daming Avenue, Nanjing, 210022, Jiangsu, China. Fanzm…
- Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, China. kongds@njucm.edu.cn.
ORCID-Profile: Desong Kong
Förderung
- Jiangsu Province Traditional Chinese Medicine Science and Technology Development Plan Project
- Jiangsu Provincial Key Research and Development Program
Zitieren
APA
Hu, Y., Geng, Q., Wang, L., Wang, Y., Huang, C., Fan, Z., & Kong, D. (2024). Research progress and application of liver organoids for disease modeling and regenerative therapy. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-024-02455-3
Vancouver
Hu Y, Geng Q, Wang L, Wang Y, Huang C, Fan Z, et al. Research progress and application of liver organoids for disease modeling and regenerative therapy. Journal of Molecular Medicine. 2024. doi:10.1007/s00109-024-02455-3
BibTeX
@article{Hu2024,
author = {Hu, Yang and Geng, Qiao and Wang, Lu and Wang, Yi and Huang, Chuyue and Fan, Zhimin and Kong, Desong},
title = {Research progress and application of liver organoids for disease modeling and regenerative therapy},
journal = {Journal of Molecular Medicine},
year = {2024},
doi = {10.1007/s00109-024-02455-3}
}
EUVIMED